Leerink Partnrs Analysts Lower Earnings Estimates for CRSP

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities researchers at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for CRISPR Therapeutics in a report issued on Thursday, July 17th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($1.78) per share for the quarter, down from their prior forecast of ($1.74). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.59) EPS, Q4 2025 earnings at ($1.44) EPS, FY2025 earnings at ($6.39) EPS and FY2026 earnings at ($6.22) EPS.

A number of other brokerages have also issued reports on CRSP. JMP Securities reissued a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Chardan Capital reissued a “buy” rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, June 26th. HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Wall Street Zen raised CRISPR Therapeutics to a “sell” rating in a research report on Friday, May 16th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $81.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, July 8th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $71.31.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $65.93 on Monday. CRISPR Therapeutics has a 1-year low of $30.04 and a 1-year high of $71.13. The stock has a market cap of $5.69 billion, a P/E ratio of -14.59 and a beta of 1.82. The stock’s 50 day simple moving average is $45.23 and its 200-day simple moving average is $42.05.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. The company’s revenue was up 71.6% compared to the same quarter last year. During the same period last year, the firm earned ($1.43) EPS.

Hedge Funds Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC lifted its holdings in CRISPR Therapeutics by 13.3% in the 1st quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company’s stock worth $345,929,000 after buying an additional 1,192,336 shares in the last quarter. Capital International Investors increased its position in shares of CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock worth $344,145,000 after purchasing an additional 816,789 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of CRISPR Therapeutics by 39.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock worth $150,029,000 after purchasing an additional 1,074,238 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of CRISPR Therapeutics by 182.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company’s stock worth $66,452,000 after purchasing an additional 1,262,560 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of CRISPR Therapeutics by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company’s stock worth $60,223,000 after purchasing an additional 33,711 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insiders Place Their Bets

In related news, Director Simeon George purchased 989,812 shares of the firm’s stock in a transaction on Wednesday, July 16th. The shares were bought at an average price of $52.03 per share, for a total transaction of $51,499,918.36. Following the acquisition, the director directly owned 1,730,179 shares in the company, valued at $90,021,213.37. This trade represents a 133.69% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the transaction, the insider owned 6,068 shares in the company, valued at $218,083.92. The trade was a 39.32% decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.